Biotech - Spark Newswire

4 minute read

FDA
News

AbbVie Offers Extended Long-Term Data From Phase 3 Study Of IMBRUVICA vs Chlorambucil For Patents With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma At American Society Of Clinical Oncology Jun. 4

Today, 10:36 AM

With up to seven years of data, progression-free and overall survival benefits continue to be observed with first-line single-agent IMBRUVICA treatment in CLL patients including selected patients with or without

ABBV

2 minute read

TRACON Pharmaceuticals Presents Data From Phase 1 Study Of Uliledlimab (TJ004309) And Tecentriq (Atezolizumab) At ASCO Meeting

By Benzinga Newsdesk

Today, 10:36 AM

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the

TCON

2 minute read

FDA
News

G1 Therapeutics Presents Phase 1 Data At ASCO Describing ‘Favorable Safety Profile and Evidence Of Antitumor Activity Of Rintodestrant Combined With Palbociclib In Patients With ER+/HER2- Advanced Breast Cancer’

By Benzinga Newsdesk

Today, 10:36 AM

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant,

GTHX

2 minute read

FDA
News

Natera Announces New Prospera Data At ATC 2021 Virtual Connect Conference

By Benzinga Newsdesk

Today, 10:36 AM

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American

NTRA

2 minute read

FDA
News

DarioHealth Releases Study Co Says Demonstrates Impact Of Personalized Digital Interventions To Improve Self-Management Of Diabetes

By Benzinga Newsdesk

Today, 10:36 AM

DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be presenting results of a new study at the 14th International Conference on Advanced Technologies

DRIO

2 minute read

Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution

By Vandana Singh

Today, 10:36 AM

Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations…

BMY

1 minute read

FDA
News

Travere Therapeutics Highlights Abstract Presentations At European Renal Association – European Dialysis and Transplant Association Congress Jun. 5-7

By Benzinga Newsdesk

Today, 10:36 AM

Travere Therapeutics (NASDAQ:TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin

TVTX

2 minute read

Curis To Host Virtual Event To Discuss Updated Clinical Data For CA-4948 In AML/MDS Presented At EHA

By Benzinga Newsdesk

Today, 10:36 AM

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a virtual KOL event to discuss progress to date for

CRIS

1 minute read

FDA
News

Zynerba Highlights Poster Presentation At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting Jun. 11

By Benzinga Newsdesk

Today, 10:36 AM

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and

ZYNE

2 minute read

FDA
News

Intellia Therapeutics Highlights Will Present Interim Clinical Data From Ongoing Phase 1 Study Of NTLA-2001 For Treatment Of Transthyretin Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting Jun. 26

By Benzinga Newsdesk

Today, 10:36 AM

Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate Late-breaking abstract selected for oral presentation on June

NTLA